107 related articles for article (PubMed ID: 25651308)
21. Improving allogeneic islet transplantation by suppressing Th17 and enhancing Treg with histone deacetylase inhibitors.
Sugimoto K; Itoh T; Takita M; Shimoda M; Chujo D; SoRelle JA; Naziruddin B; Levy MF; Shimada M; Matsumoto S
Transpl Int; 2014 Apr; 27(4):408-15. PubMed ID: 24410777
[TBL] [Abstract][Full Text] [Related]
22. Immunological shielding by induced recruitment of regulatory T-lymphocytes delays rejection of islets transplanted in muscle.
Vågesjö E; Christoffersson G; Waldén TB; Carlsson PO; Essand M; Korsgren O; Phillipson M
Cell Transplant; 2015; 24(2):263-76. PubMed ID: 24480306
[TBL] [Abstract][Full Text] [Related]
23. XIAP inhibition of β-cell apoptosis reduces the number of islets required to restore euglycemia in a syngeneic islet transplantation model.
Plesner A; Soukhatcheva G; Korneluk RG; Verchere CB
Islets; 2010; 2(1):18-23. PubMed ID: 21099289
[TBL] [Abstract][Full Text] [Related]
24. Gene expression profiling of allogeneic islet grafts in an experimental mouse model before rejection or tolerance phenotypes arise.
Choi SE; Noh JR; Seo J; Yang KJ; Kook MC; Lee CH
Transplant Proc; 2013 Mar; 45(2):597-604. PubMed ID: 23498796
[TBL] [Abstract][Full Text] [Related]
25. Synergism of a natural plant product, oleanolic acid with calcineurin inhibitor in prolonging islet allograft survival.
Angaswamy N; Tiriveedhi V; Banan B; Benshoff N; Chapman W; Mohanakumar T
Transpl Immunol; 2013 Dec; 29(1-4):64-70. PubMed ID: 24036218
[TBL] [Abstract][Full Text] [Related]
26. Harnessing the Foreign Body Reaction in Marginal Mass Device-less Subcutaneous Islet Transplantation in Mice.
Pepper AR; Pawlick R; Bruni A; Gala-Lopez B; Wink J; Rafiei Y; Bral M; Abualhassan N; Shapiro AM
Transplantation; 2016 Jul; 100(7):1474-9. PubMed ID: 27136258
[TBL] [Abstract][Full Text] [Related]
27. Selective depletion of alloreactive T cells leads to long-term islet allograft survival across a major histocompatibility complex mismatch in diabetic mice.
Hu M; Wu J; Zhang GY; Wang YM; Watson D; Yi S; Hawthorne WJ; O'Connell PJ; Alexander SI
Cell Transplant; 2013; 22(10):1929-41. PubMed ID: 23107388
[TBL] [Abstract][Full Text] [Related]
28. Long-term allogeneic islet graft survival in prevascularized subcutaneous sites without immunosuppressive treatment.
Luan NM; Iwata H
Am J Transplant; 2014 Jul; 14(7):1533-42. PubMed ID: 24909185
[TBL] [Abstract][Full Text] [Related]
29. Pancreatic islets induce CD4(+) [corrected] CD25(-)Foxp3(+) [corrected] T-cell regulated tolerance to HY-mismatched skin grafts.
Yoon IH; Choi SE; Kim YH; Yang SH; Park JH; Park CS; Kim Y; Kim JS; Kim SJ; Simpson E; Park CG
Transplantation; 2008 Nov; 86(10):1352-60. PubMed ID: 19034003
[TBL] [Abstract][Full Text] [Related]
30. HMGB1-Mediated Early Loss of Transplanted Islets Is Prevented by Anti-IL-6R Antibody in Mice.
Itoh T; Nitta T; Nishinakamura H; Kojima D; Mera T; Ono J; Kodama S; Yasunami Y
Pancreas; 2015 Jan; 44(1):166-71. PubMed ID: 25058889
[TBL] [Abstract][Full Text] [Related]
31. Tumor necrosis factor receptor superfamily member 25 (TNFRSF25) agonists in islet transplantation: Endogenous in vivo regulatory T cell expansion promotes prolonged allograft survival.
Marfil-Garza BA; Pawlick RL; Szeto J; Kroger C; Tahiliani V; Hefler J; Dadheech N; Seavey MM; Wolf J; Jasuja RR; James Shapiro AM
Am J Transplant; 2022 Apr; 22(4):1101-1114. PubMed ID: 34965021
[TBL] [Abstract][Full Text] [Related]
32. The Spleen Is an Ideal Site for Inducing Transplanted Islet Graft Expansion in Mice.
Itoh T; Nishinakamura H; Kumano K; Takahashi H; Kodama S
PLoS One; 2017; 12(1):e0170899. PubMed ID: 28135283
[TBL] [Abstract][Full Text] [Related]
33. Consistent long-term allograft survival in murine pancreatic islet transplants without immunosuppression.
Jain K; Cai BR; Patel S; Yang H; Smith BH; Suthanthiran M; Rubin AL
Transplant Proc; 1994 Dec; 26(6):3492-3. PubMed ID: 7998243
[No Abstract] [Full Text] [Related]
34. Highly Angiogenic, Nonthrombogenic Bone Marrow Mononuclear Cell-Derived Spheroids in Intraportal Islet Transplantation.
Oh BJ; Jin SM; Hwang Y; Choi JM; Lee HS; Kim G; Kim G; Park HJ; Kim P; Kim SJ; Kim JH
Diabetes; 2018 Mar; 67(3):473-485. PubMed ID: 29298810
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of transplant rejection by pretreatment of xenogeneic pancreatic islet cells with anti-ICAM-1 antibodies.
Zeng Y; Gage A; Montag A; Rothlein R; Thistlethwaite JR; Bluestone JA
Transplantation; 1994 Sep; 58(6):681-9. PubMed ID: 7940687
[TBL] [Abstract][Full Text] [Related]
36. Toll-like receptor 4 suppression leads to islet allograft survival.
Goldberg A; Parolini M; Chin BY; Czismadia E; Otterbein LE; Bach FH; Wang H
FASEB J; 2007 Sep; 21(11):2840-8. PubMed ID: 17475921
[TBL] [Abstract][Full Text] [Related]
37. A more persistent tolerance to islet allografts through bone marrow transplantation in minimal nonmyeloablative conditioning therapy.
Lee BW; Lee JI; Oh SH; Ahn YR; Chae HY; Lee MS; Lee MK; Kim KW
Transplant Proc; 2005 Jun; 37(5):2266-9. PubMed ID: 15964395
[TBL] [Abstract][Full Text] [Related]
38. Caspase inhibitor therapy enhances marginal mass islet graft survival and preserves long-term function in islet transplantation.
Emamaullee JA; Stanton L; Schur C; Shapiro AM
Diabetes; 2007 May; 56(5):1289-98. PubMed ID: 17303806
[TBL] [Abstract][Full Text] [Related]
39. Permanent acceptance of mitomycin C-treated islet allograft.
Matsuyama S; Gunji T; Ise K; Sato Y; Saito T; Gotoh M
Transplantation; 2003 Jul; 76(1):65-71. PubMed ID: 12865788
[TBL] [Abstract][Full Text] [Related]
40. Prolongation of islet xenograft survival without continuous immunosuppression.
Lacy PE; Davie JM; Finke EH
Science; 1980 Jul; 209(4453):283-5. PubMed ID: 6770465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
